四川梓橦宫药业股份有限公司 梓橦宫 832566 年度报告 2021 公告编号：2022-011 公司年度大事记 2021 年 10 月，梓橦宫注册 资本增加至 73,280,540 元，向昆 明梓橦宫增资 20,000,000 元。 2021 年 9 月，塞来昔布胶囊 申报药品注册批件，11 月，马甲 子胶囊和马甲子叶取得临床试验 批件，12 月，维格列汀片申报药 品注册批件。 2021 年，梓橦宫荣获"四川 省'万企帮万村'精准扶贫行动 先进集体"、"四川省'最佳雇 主'单位"等荣誉。 2021 年，梓橦宫取得发明专 利 6 项。 2021年8月，梓橦宫向不特定合格投资者公开发行股票 16,521,740 股，11 月正式在北京证券交易所上市！ 2 | 第一节 | 重要提示、目录和释义 4 | | --- | --- | | 第二节 | 公司概况 8 | | 第三节 | 会计数据和财务指标 10 | | 第四节 | 管理层讨论与分析 14 | | 第五节 | 重大事件 32 | | 第六节 | 股份变动及股东情况 36 | | 第七节 | 融资与利润分配情况 39 | | 第八节 | 董事、监事、高级管理 ...

Group 1: Research and Development - The company currently has no products included in the national centralized procurement list [2] - Future R&D will focus on original traditional Chinese medicine products and chemical generic drugs, including the development of Guo Liu Wei An capsules and Oseltamivir phosphate capsules [2] - The company will also conduct secondary R&D on existing exclusive traditional Chinese medicine products, such as Dongfang Weiyao capsules and Qingchang Tongbian capsules, to explore new indications [2] Group 2: Investment Projects - The company's fundraising projects are progressing as planned, with the production application for Celecoxib capsules and Vildagliptin tablets submitted, and clinical approval obtained for Guo Liu Wei An capsules [3] Group 3: Shareholding and Control - The controlling shareholder, Tang Xian, directly holds 22.47% of the company's shares and indirectly controls an additional 1.45% through a partnership, totaling 23.92% [3] - Any future plans for shareholding increases will be disclosed in accordance with regulations [3]

Group 1: Company Overview - Sichuan Zizhong Palace Pharmaceutical Co., Ltd. held an investor survey on November 2, 2021, attended by four institutions [2][3] - The survey was conducted in the company's conference room with key personnel including the Chairman and General Manager present [3] Group 2: Research and Development Plans - The company plans to increase R&D investment, focusing on the development of the original Chinese patent medicine "Qiu Liu Wei An Capsule" and secondary research on existing products like "Oriental Stomach Medicine Capsule" and "Qing Chang Tong Bian Capsule" [4] - Ongoing research projects include classic formulas such as "Er Dong Tang" and "Kai Xin San" [4] Group 3: Market Expansion Strategies - The company is exploring new marketing models for its unique Chinese patent medicines, including online sales and advertising on central channels [5] Group 4: Sales Performance - The sales revenue share of the main product, "Cerebrolysin Sodium Tablets," over the past three years is as follows: - 2018: 89.79% - 2019: 86.71% - 2020: 87.80% - First half of 2021: 90.54% [6] Group 5: Product Layout and Consistency Evaluation - Future product layout will focus on existing product lines, with chemical drugs targeting the nervous system and traditional Chinese medicine focusing on the digestive system [7] - The consistency evaluation for "Cerebrolysin Sodium Tablets" is currently in the pre-BE trial phase, with no other domestic companies having submitted applications for consistency evaluation as of the latest update [8]